Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 2(3)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07556471Phase 2Not Yet Recruiting

Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo

Role: lead

NCT07546149Phase 1Completed

A Multiple Ascending Dose Study of LW402 in Healthy Volunteers

Role: lead

NCT07370909Phase 3Not Yet Recruiting

Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT07186387Phase 2Completed

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT07179575Phase 1Recruiting

Study of LW231 in Participants With Chronic Hepatitis B

Role: lead

NCT06800157Phase 2Completed

Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis

Role: lead

NCT06311734Phase 1Completed

A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Role: lead

All 7 trials loaded